| We have working groups with the Directorate-General for Public Health, the Directorate-General for Mental Health and Addictions, and the Directorate-General for Pharmacy of the Generalitat Valenciana [Valencia Regional Government]. | ВИЧ
> ВИЧ | Регуляторное партнёрство
> Работа с регулирующими органами | 5 000 | Local | Regularly | 119026705868 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Защита интересов пациентов
> Права пациента | Регуляторное партнёрство
> Работа с регулирующими органами | 10 000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Дыхательная система
> Лёгочный фиброз | Регуляторное партнёрство
> Работа с регулирующими органами | 1 000 | National | Regularly | 119075356350 |
| IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report]. | Нервно-мышечный
> Дюшенн | Регуляторное партнёрство
> Участвовать в оценке медицинских технологий (HTA) и проверках возмещения расходов | 5 000 | National | Regularly | 119045011464 |
| We participate in Health Technology Assessments for certain medicines. | Защита интересов пациентов
> Права пациента | Регуляторное партнёрство
> Участвовать в оценке медицинских технологий (HTA) и проверках возмещения расходов | We do not communicate with patients directly | National | Rarely | 119049693177 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Защита интересов пациентов
> Права пациента | Регуляторное партнёрство
> Участвовать в оценке медицинских технологий (HTA) и проверках возмещения расходов | 10 000 | National | Sometimes | 119073823192 |
| We have recently completed IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report] assessments for Anifrolumab [for adults with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)] and Voclosporin [used to treat lupus nephritis].We are currently engaged in the IPT process for Obinutuzumab [used to treat specific blood cancers and active lupus nephritis]. | Ревматический
> Волчанка | Регуляторное партнёрство
> Участвовать в оценке медицинских технологий (HTA) и проверках возмещения расходов | 100 000 | National | Regularly | 119076492282 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | Защита интересов пациентов
> Права пациента | Регуляторное партнёрство
> Участвовать/проводить встречи с политиками/регуляторами | We do not communicate with patients directly | National | Regularly | 119012238994 |
| Community of Madrid, Department of Education, Department of Health. | Кровотечение
> Нарушения свёртываемости крови: большинство типов | Регуляторное партнёрство
> Участвовать/проводить встречи с политиками/регуляторами | 5 000 | Regional | Regularly | 119012535987 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | Пожилые люди
> Пожилые люди | Регуляторное партнёрство
> Участвовать/проводить встречи с политиками/регуляторами | We do not communicate with patients directly | National | Regularly | 119013803044 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | Редкий
> Редкие заболевания: метаболические/лизосомальные | Регуляторное партнёрство
> Участвовать/проводить встречи с политиками/регуляторами | 100 | National | Rarely | 119022231157 |
| We actively participate in meetings with the Ministry of Health, including with the HIV Control Division — covering viral hepatitis, tuberculosis, and other STIs [ITS, Infecciones de Transmisión Sexual – Sexually Transmitted Infections] — as well as with the Directorate-General for Pharmacy, among others. | ВИЧ
> ВИЧ | Регуляторное партнёрство
> Участвовать/проводить встречи с политиками/регуляторами | 100 000 | National | Regularly | 119036696548 |
| New therapeutic targets and State Health Council. | Ревматический
> Ревматические заболевания: большинство видов | Регуляторное партнёрство
> Участвовать/проводить встречи с политиками/регуляторами | 10 000 | National | Regularly | 119062924366 |
| Ministry of Health. | Сердечно-сосудистая система
> Сердечно-сосудистые заболевания & болезни сердца | Регуляторное партнёрство
> Участвовать/проводить встречи с политиками/регуляторами | 5 000 | National | Sometimes | 119072934071 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Защита интересов пациентов
> Права пациента | Регуляторное партнёрство
> Участвовать/проводить встречи с политиками/регуляторами | 10 000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Дыхательная система
> Лёгочный фиброз | Регуляторное партнёрство
> Участвовать/проводить встречи с политиками/регуляторами | 1 000 | National | Regularly | 119075356350 |
| Not in my capacity as President of ACPA [Asociación Canaria de Pacientes - Canary Islands Patients’ Association], but rather as a member of the POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] Patient Platform and as President of Feasam [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia]. | Сердечно-сосудистая система
> Сердечно-сосудистые заболевания & болезни сердца | Регуляторное партнёрство
> С другими защитниками здравоохранения | 100 | National | No | 119053738286 |
| Through ACCU [Asociaciones de Crohn y Colitis Ulcerosa - Crohn’s and Ulcerative Colitis Associations] Spain. | Желудочно-кишечный
> Желудочно-кишечный тракт: другое | Регуляторное партнёрство
> С другими защитниками здравоохранения | 1 000 | Regional | Sometimes | 119053970542 |
| FEDER [Federación Española de Enfermedades Raras – Spanish Federation of Rare Diseases] and EURORDIS [European Rare Disease Organisation]. | Редкий
> Болезнь Вильсона | Регуляторное партнёрство
> С другими защитниками здравоохранения | 100 | National | Regularly | 119078667611 |
| Legislation pertaining to patients living with a rare disease. | Редкий
> Редкие заболевания: генетические | Влияние на политику и законодательство
> Влияние на политику и законодательство в сфере здравоохранения | 1 000 | National | Regularly | 119012112198 |
| Legal, policy, institutional, and corporate actions. | Безопасность пациента
> Ятрогенный | Влияние на политику и законодательство
> Влияние на политику и законодательство в сфере здравоохранения | 1 000 | National | Regularly | 119045262726 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Желудочно-кишечный
> Целиакия | Влияние на политику и законодательство
> Влияние на политику и законодательство в сфере здравоохранения | 100 000 | National | Regularly | 119053766557 |
| Letters were submitted to the Ministry of Health. | Редкий
> Редкие заболевания: генетические | Влияние на политику и законодательство
> Влияние на политику и законодательство в сфере здравоохранения | 100 | National | Regularly | 119065350505 |
| In our country [Spain] it is challenging, but we do have channels through which we are able to communicate. | Печень
> Заболевания печени: трансплантации | Влияние на политику и законодательство
> Влияние на политику и законодательство в сфере здравоохранения | 5 000 | National | Rarely | 119069515067 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Дыхательная система
> Лёгочный фиброз | Влияние на политику и законодательство
> Влияние на политику и законодательство в сфере здравоохранения | 1 000 | National | Regularly | 119075356350 |
| Ongoing contact and coordination with César Hernández [Director General of the Common Portfolio of the NHS and Pharmacy within the Spanish Ministry of Health]. | Редкий
> Редкие болезни: большинство типов | Влияние на политику и законодательство
> Влияние на политику и законодательство в сфере здравоохранения | 100 000 | National | Regularly | 119078056907 |
| In the Community of Madrid, we are consulted on medicines and their importance for our patient community. | Кровотечение
> Нарушения свёртываемости крови: большинство типов | Влияние на политику и законодательство
> Участвовать в публичных слушаниях и консультациях | 5 000 | Regional | Regularly | 119036712634 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Хроническое
> Хронические заболевания в целом | Влияние на политику и законодательство
> Участвовать в публичных слушаниях и консультациях | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Желудочно-кишечный
> Целиакия | Влияние на политику и законодательство
> Участвовать в публичных слушаниях и консультациях | 100 000 | National | Regularly | 119053766557 |
| We do not intervene in pricing decisions; however, we advocate for patient and stakeholder interests before the relevant public authorities. | Неврологический
> Рассеянный склероз | Влияние на политику и законодательство
> Участвовать в публичных слушаниях и консультациях | 5 000 | Local | Regularly | 119064523376 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Желудочно-кишечный
> Целиакия | Влияние на политику и законодательство
> Мобилизовать парламентариев и политических лидеров | 100 000 | National | Regularly | 119053766557 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | ВИЧ
> ВИЧ | Влияние на политику и законодательство
> Мобилизовать парламентариев и политических лидеров | 5 000 | Local | Regularly | 119072832940 |
| Through the political action initiatives we undertake and promote. | Редкий
> Редкие заболевания: генетические | Влияние на политику и законодательство
> Мобилизовать парламентариев и политических лидеров | 100 | International | Regularly | 119078207611 |
| Legislation pertaining to patients living with a rare disease. | Редкий
> Редкие заболевания: генетические | Влияние на политику и законодательство
> Выступать за законопроекты и права по защите пациентов | 1 000 | National | Regularly | 119012112198 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Желудочно-кишечный
> Целиакия | Влияние на политику и законодательство
> Участвовать в разработке законодательства в области общественного здравоохранения | 100 000 | National | Regularly | 119053766557 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | Рак
> Рак: поджелудочной железы | Влияние на политику и законодательство
> Устранение барьеров/аномалий в медицинской помощи | 1 000 | National | Rarely | 119012120290 |
| Nucleoside therapy for TK2d has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | Редкий
> Редкие заболевания: генетические | Пропаганда доступного ценообразования
> Выступать за справедливое ценообразование на лекарства | 100 | National | Regularly | 119070360428 |
| Reimbursement of biological treatments. | Дыхательная система
> ХОБЛ | Пропаганда доступного ценообразования
> Выступать за справедливое ценообразование на лекарства | 1 000 | National | Regularly | 119078128994 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Хроническое
> Хронические заболевания в целом | Пропаганда доступного ценообразования
> Участвовать в переговорах комиссии по пересмотру цен | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Nucleoside therapy for TK2d [Thymidine Kinase 2 deficiency] has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | Редкий
> Редкие заболевания: генетические | Пропаганда доступного ценообразования
> Участвовать в переговорах комиссии по пересмотру цен | 100 | National | Regularly | 119070360428 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | Редкий
> Редкие заболевания: метаболические/лизосомальные | Пропаганда доступного ценообразования
> Отстаивание включения продукта в списки возмещения/национальные формуляры | 100 | National | Rarely | 119022231157 |
| The priority is not so much determining the price, but securing reimbursement. | Дыхательная система
> Дыхательная система: большинство состояний | Пропаганда доступного ценообразования
> Отстаивание включения продукта в списки возмещения/национальные формуляры | 5 000 | National | Regularly | 119054105408 |
| … Reimbursement of biological therapies. | Дыхательная система
> ХОБЛ | Пропаганда доступного ценообразования
> Отстаивание включения продукта в списки возмещения/национальные формуляры | 1 000 | National | Regularly | 119078128994 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | Рак
> Рак: поджелудочной железы | Улучшение путей доступа
> Обеспечение равного доступа к лекарствам/медицинской помощи | 1 000 | National | Rarely | 119012120290 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | Защита интересов пациентов
> Права пациента | Улучшение путей доступа
> Обеспечение равного доступа к лекарствам/медицинской помощи | We do not communicate with patients directly | National | Regularly | 119012238994 |
| We participate in the sampling of products entering public tender processes. | Эндокринная
> Диабет (оба типа: 1 и 2) | Улучшение путей доступа
> Обеспечение равного доступа к лекарствам/медицинской помощи | 5 000 | Regional | Regularly | 119019803062 |
| We successfully halted the withdrawal of public reimbursement for SYSADOAs [Symptomatic Slow-Acting Drugs for Osteoarthritis], an effective and well-established treatment for osteoarthritis. | Кость
> Остеоартрит и остеопороз | Улучшение путей доступа
> Обеспечение равного доступа к лекарствам/медицинской помощи | 5 000 | National | Regularly | 119022568142 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Хроническое
> Хронические заболевания в целом | Улучшение путей доступа
> Обеспечение равного доступа к лекарствам/медицинской помощи | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Removal of the prior authorisation requirement for triple therapy [Doctors in Spain needed administrative approval from the National Health System to prescribe or fully reimburse a combined respiratory drug in a single inhaler.] | Дыхательная система
> ХОБЛ | Улучшение путей доступа
> Обеспечение равного доступа к лекарствам/медицинской помощи | 1 000 | National | Regularly | 119078128994 |
| Providing guidance from the patient perspective. | Редкий
> Редкие болезни: большинство типов | Доказательный вклад пациента
> Используйте данные о пациентах для принятия решений | 1 000 | National | Regularly | 119055416525 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Защита интересов пациентов
> Права пациента | Доказательный вклад пациента
> Используйте данные о пациентах для принятия решений | 10 000 | National | Sometimes | 119073823192 |
| They consult us. | Неврологический
> Фибромиалгия | Доказательный вклад пациента
> Используйте данные о пациентах для принятия решений | Do not know | Local | Sometimes | 119075536668 |
| ... Advise from the patient's perspective. Influence through formal participation or institutional pressure. Contribute social evidence and patient experience. Contributing real-world evidence and patient experience. | Редкий
> Редкие болезни: большинство типов | Доказательный вклад пациента
> Предоставление реальных доказательств (RWE) регуляторным органам | 1 000 | National | Regularly | 119055416525 |
| ... Contributing real-world evidence and patient experience. | Редкий
> Редкие болезни: большинство типов | Доказательный вклад пациента
> Используйте истории пациентов и нарративы на основе личного опыта | 1 000 | National | Regularly | 119055416525 |
| Associations of family members of patients with Alzheimer's disease [interacting with drug regulators]. | Нейродегенеративные
> Болезнь Альцгеймера | Доказательный вклад пациента
> Используйте истории пациентов и нарративы на основе личного опыта | We do not communicate with patients directly | Regional | Regularly | 119067801531 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Хроническое
> Хронические заболевания в целом | Доказательный вклад пациента
> Переводите доказательства и аналитические данные в политические рекомендации | We do not communicate with patients directly | National | Regularly | 119052165521 |
| … We raise concerns on issues such as adverse drug reactions. | Пожилые люди
> Пожилые люди | Диагностика и доставка лекарств
> Обеспечьте безопасное и эффективное применение лекарств | We do not communicate with patients directly | National | Regularly | 119013803044 |
| By providing information on the indications for which administration of the orphan medicinal product is clearly necessary, as well as the circumstances in which alternative forms of healthcare provision may be expected or appropriate. | Редкий
> Синдром фон Гиппеля-Линдау | Диагностика и доставка лекарств
> Обеспечьте безопасное и эффективное применение лекарств | 100 | National | Rarely | 119046844450 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Защита интересов пациентов
> Права пациента | Диагностика и доставка лекарств
> Обеспечьте безопасное и эффективное применение лекарств | 10 000 | National | Sometimes | 119073823192 |
| … We also issue practice recommendations for members of the ESGG [Sociedad Española de Geriatría y Gerontología – Spanish Society of Geriatrics and Gerontology]. | Пожилые люди
> Пожилые люди | Диагностика и доставка лекарств
> Участвовать в разработке клинических руководств | We do not communicate with patients directly | National | Regularly | 119013803044 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | Пожилые люди
> Пожилые люди | Институциональное управление
> Обеспечить представительство в государственных консультативных органах | We do not communicate with patients directly | National | Regularly | 119013803044 |
| With public authorities. | Кровотечение
> Гемофилия | Институциональное управление
> Обеспечить представительство в государственных консультативных органах | 100 | Regional | Regularly | 119053275561 |
| Not directly through ACPA [Asociación Comarcal de Personas con Ansiedad - Regional Association of People with Anxiety], but through Rafael Martínez in his capacity as President of FEASAM [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia] and as a member of the POP [Patients’ Organisations Platform - Plataforma de Organizaciones de Pacientes] Patient Platform. | Сердечно-сосудистая система
> Сердечно-сосудистые заболевания & болезни сердца | Институциональное управление
> Обеспечить представительство в государственных консультативных органах | 100 | Local | No | 119053750627 |
| Providing guidance from the patient perspective. Exercising influence through formal participation or institutional advocacy. | Редкий
> Редкие болезни: большинство типов | Институциональное управление
> Обеспечить представительство в государственных консультативных органах | 1 000 | National | Regularly | 119055416525 |
| We do not intervene in pricing decisions; however, we do represent and defend the interests of those we advocate for before the relevant public authorities. | Неврологический
> Рассеянный склероз | Институциональное управление
> Обеспечить представительство в государственных консультативных органах | 5 000 | Local | Regularly | 119064523376 |
| We represent the interests of patients, but we do not intervene in pricing decisions. | Неврологический
> Рассеянный склероз | Институциональное управление
> Обеспечить представительство в государственных консультативных органах | 10 000 | Regional | Rarely | 119065344758 |
| We are members of the Patient Committee of the Valencian Community. | ВИЧ
> ВИЧ | Институциональное управление
> Обеспечить представительство в государственных консультативных органах | 10 000 | Regional | No | 119072419533 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | ВИЧ
> ВИЧ | Институциональное управление
> Обеспечить представительство в государственных консультативных органах | 5 000 | Local | Regularly | 119072832940 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Защита интересов пациентов
> Права пациента | Институциональное управление
> Обеспечить представительство в государственных консультативных органах | 10 000 | National | Sometimes | 119073823192 |
| The organisation has held Public Interest status, as designated by the Spanish Ministry of the Interior, since 2008. | Неврологический
> Неврологические: большинство состояний | Институциональное управление
> Поддерживать официальный статус организации, действующей в общественных интересах или являющейся благотворительной | 1 000 | Local | Rarely | 119054524092 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. | ВИЧ
> ВИЧ | Институциональное управление
> Поддерживать официальный статус организации, действующей в общественных интересах или являющейся благотворительной | 5 000 | Local | Regularly | 119072832940 |
взаимодействия
действия и защита интересов
19 упоминания
